Trial Profile
Impact of raloxifene, eldecalcitol and their combination therapy on bone indices in postmenopausal subjects with osteoporosis and chronic kidney disease stage 3: Re Bone Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2022
Price :
$35
*
At a glance
- Drugs Eldecalcitol (Primary) ; Raloxifene (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 15 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2015 New trial record